On January 2, Gelonghui reported that GRANDPHARMA (00512.HK) announced that the group’s Global innovative temperature-sensitive embolic product GPN00289 has recently completed the enrollment of the first patient in the registration clinical study for transarterial chemotherapy embolization of primary liver cancer in China.
This study is a prospective, multi-center, randomized, parallel-controlled clinical study aimed at evaluating the safety and efficacy of GPN00289 for transarterial chemotherapy embolization of primary liver cancer. The completion of the first patient enrollment in this registration clinical study for GPN00289 is another significant research and development progress made by the group in the field of nuclear medicine for anti-tumor therapy in interventional oncology.
